(Hungarian Brain Research Program 3.0 (NAP 3.0) 2022–2025)
(TKP2021-EGA-25)
Subjects:
Psychiatry
The impact of suicide on our societies, mental healthcare, and public health is beyond
questionable. Every year approximately 700 000 lives are lost due to suicide around
the world (WHO, 2021); more people die by suicide than by homicide and war. Although
suicide is a key issue and reducing suicide mortality is a global imperative, suicide
is a highly complex biopsychosocial phenomenon, and in spite of several suicidal models
developed in recent years and a high number of suicide risk factors identified, we
still have neither a sufficient understanding of underpinnings of suicide nor adequate
management strategies to reduce its prevalence. The present paper first overviews
the background of suicidal behavior including its epidemiology, prevalence, age and
gender correlations and its association with neuropsychiatric disorders as well as
its clinical assessment. Then we give an overview of the etiological background, including
its biopsychosocial contexts, genetics and neurobiology. Based on the above, we then
provide a critical overview of the currently available intervention options to manage
and reduce risk of suicide, including psychotherapeutic modalities, traditional medication
classes also providing an up-to-date overview on the antisuicidal effects of lithium,
as well as novel molecules such as esketamine and emerging medications and further
molecules in development. Finally we give a critical overview on our current knowledge
on using neuromodulatory and biological therapies, such as ECT, rTMS, tDCS and other
options.